Incidence of cutaneous adverse events after exposure to tenofovir-emtricitabine in HIV-uninfected vs HIV-infected patients: Pharmacovigilance analysis of a large Midwestern US patient population from the RADAR (Research on Adverse Drug events And Reports) - 22/08/19
Cory Kosche, BS, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Andrew Para, MD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Hajar Abu-Zayed, BS, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Eran Gwillam, MD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Lauren Sadowsky, BS, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Rachel Lefferdink, MD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Frank J. Palella Jr, MD, Department of Medicine, Division of Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, IL; Joaquin Brieva, MD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Dennis P. West, PhD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Beatrice Nardone, MD, PhD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL
Le texte complet de cet article est disponible en PDF. Commercial support: None identified. |
Vol 81 - N° 4S1
P. AB80 - octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?